The FDA Approves Aducanumab for Alzheimer’s Disease, Raising Important Scientific Questions1

Jack C. de la Torre; Francisco Gonzalez-Lima

doi:10.3233/jad-210736

journal article Aug 03, 2021

The FDA Approves Aducanumab for Alzheimer’s Disease, Raising Important Scientific Questions1

Jack C. de la Torre Francisco Gonzalez-Lima

Journal of Alzheimer’s Disease Vol. 82 No. 3 pp. 881-882 · SAGE Publications

View at Publisher Save 10.3233/jad-210736

Topics

No keywords indexed for this article. Browse by subject →

References

2

[1]

Holmes "Long-term effects of Abeta42 immunization in Alzheimer’s disease: Follow-up of a randomized, placebo-controlled phase I trial" Lancet (2008) 10.1016/s0140-6736(08)61075-2

[2]

Nordhaus WD (2021) The Spirit of Green: The Economics of Collisions and Contagions in a Crowded World. Princeton University Press, Princeton and Oxford. 10.1515/9780691215396

Metrics

24

Citations

2

References

Details

Published: Aug 03, 2021
Vol/Issue: 82(3)
Pages: 881-882

Authors

J

Jack C. de la Torre

Professor of Neuropsychology (Adjunct), Department of Psychology, University of Texas at Austin, Austin, TX, USA; Professor of Physiology (Hon), University of Valencia Faculty of Medicine, Valencia, Spain

F

Francisco Gonzalez-Lima

George I. Sanchez Centennial Professor, Department of Psychology, Institute for Neuroscience, Director, Texas Consortium in Behavioral Neuroscience, University of Texas at Austin, Austin, TX, USA

Cite This Article

Jack C. de la Torre, Francisco Gonzalez-Lima (2021). The FDA Approves Aducanumab for Alzheimer’s Disease, Raising Important Scientific Questions1. Journal of Alzheimer’s Disease, 82(3), 881-882. https://doi.org/10.3233/jad-210736

The FDA Approves Aducanumab for Alzheimer’s Disease, Raising Important Scientific Questions1

You May Also Like